Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)
Latest Information Update: 15 Apr 2022
At a glance
- Drugs Colchicine (Primary)
- Indications Cardiovascular disorders; COVID 2019 infections
- Focus Therapeutic Use
- Acronyms COLHEART-19
- 11 Apr 2022 Planned End Date changed from 1 Jan 2022 to 31 Dec 2022.
- 12 Mar 2021 Status changed from recruiting to suspended. Reason the study was stopped:Published RECOVERY trial provides evidence that further recruitment would not provideconclusive proof of worthwhile benefit of Colchicine on COVID patients.
- 12 Mar 2021 Planned primary completion date changed from 1 Sep 2021 to 12 Mar 2021.